Silva Markovic-Plese, MD, PhD
Professor
Contact
Silva Markovic-Plese, MD, PhD
Professor
Education
Medical School
MD, University of Zagreb Medical School, Croatia
PhD, University of Zagreb, Croatia
Residency
Yale University School of Medicine
Harvard University Medical School
Publications
- Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS)
- Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: An open-label two-arm trial
- IL-11 induces Th17 cell responses in patients with early relapsing-remitting multiple sclerosis
- Immunomodulatory therapies for relapsing-remitting multiple sclerosis: Monoclonal antibodies, currently approved and in testing
- Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly
- The role of fractalkine (CX3CL1) in regulation of CD4+ cell migration to the central nervous system in patients with relapsing-remitting multiple sclerosis
- IL-11 in multiple sclerosis
- Dermatomyositis as a presentation of neuromyelitis optica spectrum disorder
- The role of endogenous IFN-β in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis
- Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: A 24-week, controlled pilot study
- Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis
- Diffusion tensor imaging based network analysis detects alterations of neuroconnectivity in patients with clinically early relapsing-remitting multiple sclerosis
- Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis
- Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate
- Pathogenic features of CD4+CD28- T cells in immune disorders
- CX3CR1 drives cytotoxic CD4+CD28- T cells into the brain of multiple sclerosis patients
- Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis
- Protein changes in CSF of HIV-infected patients: Evidence for loss of neuroprotection
- B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis
- A role of IL-1R1 signaling in the differentiation of Th17 cells and the development of autoimmune diseases
Board Certification
American Board of Psychiatry and Neurology
Hospital Appointment
Thomas Jefferson University Hospitals